Skip to content

COOLing for Ischaemic Stroke Trial. A phase II randomised clinical trial.

COOLing for Ischaemic Stroke Trial. A phase II randomised clinical trial. - COOLIST: COOLing for Ischaemic Stroke Trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON39710
Enrollment
48
Registered
2011-04-12
Start date
2011-10-28
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic stroke

Interventions

Surface cooling to 34, 34.5, or 35°C maintained for 24 hours or standard treatment.

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. A clinical diagnosis of acute ischaemic stroke; 2. A possibility to initiate cooling within 4.5 hours of stroke onset. Onset time for patients who awoke with symptoms is defined as the last time the patient was awake without symptoms of stroke; 3. Score on the National Institutes of Health Stroke Scale (NIHSS) >= 6; 4. Age >= 18 years; 5. Written informed consent by the patient or a legal representative.

Exclusion criteria

Exclusion criteria: 1. Evidence from a CT or MRI scan or from other pre-randomisation investigations of an intracranial haemorrhage, a brain tumour, encephalitis, or any diagnosis other than acute ischaemic stroke likely to be the cause of the symptoms. Haemorrhagic transformation of the infarct is not an exclusion criterion, except when there is a parenchymal haematoma covering more than 30% of the infarcted area, with significant space-occupying effect, or when there is a bleeding remote from the infarcted area (PH2 on Fiorelli*s scale); 2. Conditions that may be complicated by hypothermia, such as haematological dyscrasias(including oral anticoagulant treatment with INR >=1.7 or a platelet count 50 mg/L, or a clinical diagnosis of sepsis; 3. Blood oxygen saturation below 92% without use of oxygen therapy or below 94 % with a maximum of 2 L/min oxygen delivered nasally; 4. Bradycardia ( 120 kg; 6. Pre-stroke score on the modified Rankin Scale (mRS) > 2; 7. Allergy to pethidine or buspirone, use of a monoamine oxidase inhibitor in the previous 14 days, hepatic or severe renal dysfunction, or asthma. Severe hepatic dysfunction is defined as liver enzymes increased above two times above the upper limit of normal, and severe renal dysfunction as a glomerular filtration rate

Design outcomes

Primary

MeasureTime frame
Feasibility, defined as the number of patients that has successfully completed the treatment strategy they had been assigned to.

Secondary

MeasureTime frame
The main secondary outcome measures include: 1. Time to target temperature; 2. Stability at target; 3. Complications; 4. Score on the modified Rankin scale at three months.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)